Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

R Dennin

Showing results (11-20 of 13) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 13 results.
Journal of Interferon Research|January 1, 1983
Cell and virus sensitivity studies with recombinant human alpha interferonsM J Kramer, R Dennin, C Kramer, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 1, 1992
Phase I trial of murine monoclonal antibody L6 in combination with subcutaneous interleukin-2 in patients with advanced carcinoma of the breast, colorectum, and lungL D Ziegler, P Palazzolo, J Cunningham, et al.
Blood|September 15, 1991
Administration of interleukin-2 (IL-2) results in increased plasma concentrations of IL-5 and eosinophilia in patients with cancerC van Haelst Pisani, J S Kovach, H Kita, et al.
Pageof 2

Showing results (11-20 of 13) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 13 results.
Journal of Interferon Research|January 1, 1983
Cell and virus sensitivity studies with recombinant human alpha interferonsM J Kramer, R Dennin, C Kramer, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 1, 1992
Phase I trial of murine monoclonal antibody L6 in combination with subcutaneous interleukin-2 in patients with advanced carcinoma of the breast, colorectum, and lungL D Ziegler, P Palazzolo, J Cunningham, et al.
Blood|September 15, 1991
Administration of interleukin-2 (IL-2) results in increased plasma concentrations of IL-5 and eosinophilia in patients with cancerC van Haelst Pisani, J S Kovach, H Kita, et al.
Pageof 2